HUMAN MONOCLONAL ANTIBODY SPECIFIC FOR LIPOPOLYSACCHARIDES (LPS) OF THE PSEUDOMONAS AERUGINOSA IATS O11 SEROTYPE

• Main Authors: LANG, ALOIS B, ZUERCHER, ADRIAN, HORN, MICHAEL P, IMBODEN, MARTIN A
• Format: Patent
• Language: English; French
• Published: 10.01.2012
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody. La présente invention concerne un anticorps monoclonal humain spécifique au stéréotype IATS O11 deP. aeruginosa, un hybridome qui le produit, des acides nucléiques qui le codent, ainsi que des cellules hôtes transfectées au moyen de celui-ci. La présente invention concerne en outre des procédés de production dudit anticorps monoclonal. De plus, la présente invention concerne des compositions pharmaceutiques comprenant au moins un anticorps ou au moins un acide nucléique codant ledit anticorps.